UroGen Pharma (URGN) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
UroGen Pharma (URGN) has outperformed Xencor (XNCR) over the past year, gaining 124.3% versus a gain of 88.6%. Over five years, URGN leads with a +116.4% price change compared with -36.0% for XNCR. Xencor is the larger company by market cap ($1.83 billion vs $1.80 billion), about 1.0 times the size, while UroGen Pharma is growing revenue faster (+21.4% vs +13.7%).
Xencor converts more of its revenue into profit, with a net margin of -73.2% versus -139.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | URGN | XNCR |
|---|---|---|
| Share price | $36.83 | $24.63 |
| Market cap | $1.80B | $1.83B |
| 1-day change | -0.41% | +0.53% |
| YTD return | +57.26% | +60.88% |
| 1-year return | +124.30% | +88.59% |
| 5-year return | +116.39% | -35.98% |
| Forward P/E | 13.18 | — |
| EPS (TTM) | $-1.97 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $109.79M | $125.58M |
| Revenue growth (YoY) | +21.45% | +13.65% |
| Net income (latest FY) | $-153.49M | $-91.92M |
| Gross margin | 88.66% | — |
| Operating margin | -113.73% | -141.35% |
| Net margin | -139.81% | -73.20% |
| 52-week high | $50.81 | $30.61 |
| 52-week low | $15.86 | $10.38 |
| Distance from 52-week high | -27.51% | -19.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +62.91% | +27.57% |
| Average volume | 849.01K | 1.32M |
| Shares outstanding | 48.88M | 74.35M |
| Employees | 300 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed XNCR by 35.7 percentage points over the past year.
- Xencor is more profitable, keeping -73.2 cents of every revenue dollar as net income versus -139.8 cents for UroGen Pharma.
- UroGen Pharma grew revenue faster in its latest fiscal year (+21.45% vs +13.65%).
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
URGN vs XNCR FAQ
Which is bigger, UroGen Pharma or Xencor?
Xencor (XNCR) is larger, with a market capitalization of $1.83B compared with $1.80B for UroGen Pharma (URGN).
Which stock has performed better over the past year, URGN or XNCR?
URGN returned +124.30% over the past 12 months, compared with +88.59% for XNCR (price return, excluding dividends). Past performance does not predict future results.
Are UroGen Pharma and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.